ASCO abstracts available for search

ASCO abstracts are now available for search
Direct links to major kinase abstracts can be found under the ASCO section of KinaseCentral.com

Sorafenib shows broader anti AML cell activity than Imatinib or Sunitinib

In vitro analysis of multikinas inhibitors imatinib, sorafenib, and sunitinib in human AML cell lines show sorafenib to inhibit the most blast samples

Scientists from H Lee Moffitt describe Rb/Raf-1 inhibitors

H Lee Moffitt Scientists descive a new Rb/Raf-1 disruptor 251 (RRD-251), that potently and selectively disrupts the Rb/Raf-1 but not Rb/E2F, Rb/prohibitin, Rb/cyclin E, and Rb/HDAC binding.

Aegera’s JAK2 inhibitor LS-104 induces ap

LS104 inhibited JAK2 kinase activity in vitro and strongly inhibited cytokine-independent growth of endogenous erythroid colonies

Src inhibitor SKI-606 (bosutinib) inhibits signaling pathways involved in controlling tumor cell motility and invasion

Wyeth’s Src inhibitor at SKI-606 decreased cell motility and invasion of breast cancer cell lines. SKI-606 inhibits the phosphorylation of focal adhesion (FAK), proline-rich tyrosine kinase 2 (Pyk2), and Crk-associated substrate.

US and WO patent update for the week ending 05/16

US and WO kinase patents have been updated for this week at KinaseCentral.com

Cerep publish docking strategy for the generation of kinase inhibitors

In this weeks J Med Chem Cerep scientists describe a high-throughput docking strategy for the indetification of kinase inhibitors in silico.

Kirin TGF-beta Kinase inhbiitors

Kirin publish synthesis of [2-(4-quinolyloxy)phenyl]methanone transforming growth factor-β inhibitors. Data show these compounds interact with the ATP-binding pocket of the transforming growth factor-β type I receptor kinase domain.